Insider Form 4: Decheng/Dr. Cui Disclose Sales in BeyondSpring (BYSI)
Rhea-AI Filing Summary
Decheng Capital entities and Dr. Xiangmin Cui reported a series of open-market sales of BeyondSpring Inc. (BYSI) ordinary shares in August 2025. Decheng Capital China Life Sciences USD Fund III, L.P. sold a total of 5,710 ordinary shares across 08/21/2025–08/25/2025 at weighted average prices of approximately $1.79, $1.75, and $1.77, leaving Fund III with 1,913,734 shares beneficially owned. Related Decheng vehicles also report indirect holdings of 1,617,409 and 891,734 shares respectively. All holdings are reported as indirect and the filings disclose customary disclaimers of direct beneficial ownership by the general partners and manager.
Positive
- Timely, complete disclosure of insider transactions with signed Form 4 filings and explanatory footnotes
Negative
- Insider sales occurred: 5,710 shares sold across 08/21/2025–08/25/2025 at weighted-average prices of approximately $1.75–$1.79
Insights
TL;DR: Decheng-affiliated funds sold a small number of BYSI shares in multiple trades; holdings remain concentrated and disclosed as indirect.
The reported disposals total 5,710 shares executed across three dates with weighted prices in the $1.75–$1.79 range. Post-sale beneficial holdings reported are sizable for the funds involved (Fund III: 1.91M; Fund II: 1.62M; Healthcare: 0.89M), indicating continued meaningful exposure despite the sales. The transactions are disclosed as indirect holdings through fund/G.P. structures and include standard footnotes about price ranges and disclaimers. On face value this appears to be routine portfolio-level selling rather than a change in control or operational development.
TL;DR: Insider-sale disclosures are complete and signed; no explicit change in voting/control is reported.
The Form 4s identify the reporting parties, their relationships to the issuer (director and 10% owner flags), and provide weighted-average price footnotes as required. Signatures from fund general partners and Dr. Cui are present. The filings reaffirm that beneficial ownership is indirect and include disclaimers limiting attributed ownership to pecuniary interest. From a governance perspective, transparency requirements are met; the filings contain no statements indicating altered board composition, agreements, or transfer of control.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 300 | $1.77 | $531.00 |
| Sale | Ordinary Shares | 2,376 | $1.75 | $4K |
| Sale | Ordinary Shares | 3,034 | $1.79 | $5K |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.74 to $1.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
